Michael Salter, MD
Glaucoma Specialist · Huntsville, ALNPI 1376833905
Payments from drug & device makers
Across 445 payments — averaging $42.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Alcon$4K
- Carl Zeiss Meditec USA, Inc.$1K
- Glaukos Corporation$951
- Bausch & Lomb, A Division Of Bausch Health US, LLC$461
- NEW World Medical,inc.$452
- plus $3K from 22 others
What the payments were for
- Consulting fees$1,3007%
- Speaking & faculty fees$4,10022%
- Food & beverage$11,97464%
- Other$1,3317%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 136 | $8,869 |
| Alcon | 144 | $3,948 |
| Carl Zeiss Meditec USA, Inc. | 2 | $1,331 |
| Glaukos Corporation | 28 | $951 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $461 |
| NEW World Medical,inc. | 18 | $452 |
| Sight Sciences, Inc. | 16 | $429 |
| Ivantis, Inc | 10 | $410 |
| Aerie Pharmaceuticals, Inc. | 6 | $212 |
| Bausch & Lomb Americas Inc. | 7 | $208 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $202 |
| Tarsus Pharmaceuticals, Inc. | 9 | $163 |
| Sun Pharmaceutical Industries Inc. | 7 | $157 |
| AstraZeneca | 5 | $152 |
| Novartis | 8 | $151 |
| Thea Pharma Inc. | 5 | $96 |
| Oyster Point Pharma, Inc. | 4 | $81 |
| Rxsight Inc | 3 | $69 |
| Mallinckrodt Hospital Products Inc. | 3 | $65 |
| Ocular Therapeutix, Inc. | 3 | $57 |
| Akorn Operating Company LLC | 3 | $52 |
| Eyepoint US, Inc. | 3 | $45 |
| Iridex Corporation | 2 | $40 |
| Kala Pharmaceuticals, Inc. | 1 | $25 |
| Nova Eye, Inc. | 1 | $24 |
| Akorn, Inc. | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$4,298
- XEN$2,170
- ARTEVO 800$1,331
- Clareon$495
- DURYSTA$252
- iStent inject Trabecular Micro-Bypass Stent System$248
- LenSx$225
- VYZULTA$223
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$165
- iAccess Precision Blade$165
- LOTEMAX SM$164
- Clareon PanOptix Pro$145
- Tecnis Simplicity$135
- ARGOS$134
- Rhopressa$125
- Rocklatan$125
- iStent Trabecular Micro-Bypass Stent System$124
- Hydrus Microstent$123
- Ahmed Glaucoma Valve$102
- Kahook Dual Blade$102
How this compares
Too few glaucoma specialist providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 199 | $105,813 |
| CombiganBrimonidine Tartrate/Timolol | 121 | $57,700 |
| RestasisCyclosporine | 52 | $57,540 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 173 | $43,012 |
| VyzultaLatanoprostene Bunod | 91 | $39,761 |
| RocklatanNetarsudil Mesylat/Latanoprost | 71 | $37,396 |
| Latanoprost | 1,785 | $32,033 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,206 | $31,840 |
| TafluprostTafluprost/Pf | 115 | $27,333 |
| Brimonidine Tartrate | 530 | $26,389 |
| Alphagan PBrimonidine Tartrate | 41 | $24,379 |
| Prednisolone Acetate | 508 | $20,400 |
| Travoprost | 104 | $19,065 |
| RhopressaNetarsudil Mesylate | 37 | $18,186 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 88 | $17,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $8,869 | $245,433413 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $212 | $55,581108 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $208 | $39,76191 claims |
| AlconSimbrinza | $3,948 | $17,75276 claims |
| Akorn, Inc.Zioptan | $24 | $11,18917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Huntsville
- Blythe MonheitBirmingham$5K
- Yaffa WeaverMobile$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.